Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Feb 2023
The medicine is a miracle, but only if you can afford it
7 February 2023 - A wave of new treatments have cured devastating diseases. When the costs are too much, even for ...
Posted by Michael Wonder on 07 Feb 2023
Valeo Pharma obtains public reimbursement for Onstryv in Quebec
7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec. ...
Posted by Michael Wonder on 07 Feb 2023
Rocket Pharmaceuticals receives FDA regenerative medicine advanced therapy designation for RP-A501 gene therapy for Danon disease
7 February 2023 - Rocket Pharmaceuticals today announced that the US FDA has granted regenerative medicine advanced therapy designation to ...
Posted by Michael Wonder on 07 Feb 2023
Aldeyra Therapeutics announces FDA acceptance of new drug application for reproxalap for the treatment of dry eye disease
7 February 2023 - PDUFA date is 23 November 2023. ...
Posted by Michael Wonder on 07 Feb 2023
Takeda announces MHRA approval for dengue virus vaccine candidate Qdenga
7 February 2023 - The decision from the MHRA will enable eligible individuals from the UK, who are travelling to dengue ...
Posted by Michael Wonder on 07 Feb 2023
Forxiga approved in the EU for the treatment of symptomatic chronic heart failure
7 February 2023 - First and only heart failure therapy with proven mortality benefit across the full ejection fraction range ...
Posted by Michael Wonder on 06 Feb 2023
International collaboration
26 January 2023 - SMC, as part of Healthcare Improvement Scotland, are part of an international collaboration. ...
Posted by Michael Wonder on 06 Feb 2023
Respiri becomes first Australian company to receive US reimbursements
6 February 2023 - The medical device manufacturer can now have its patented wheezo device, used for remote patient monitoring programs, ...
Posted by Michael Wonder on 06 Feb 2023
Medical technology strategy
3 February 2023 - This document presents the inaugural UK medtech strategy and the timing could not be better. ...
Posted by Michael Wonder on 06 Feb 2023
Sage Therapeutics and Biogen announce FDA accepts filing of new drug application and grants priority review of zuranolone in the treatment of major depressive disorder and post-partum depression
6 February 2023 - Zuranolone is being evaluated as a potential 14 day, rapid acting, once daily, oral medication to treat ...
Posted by Michael Wonder on 06 Feb 2023
Endogena Therapeutics receives US FDA fast track designation for EA-2353 for the treatment of retinitis pigmentosa
6 February 2023 - Endogena Therapeutics announced today that the US FDA has designated the investigation of EA-2353 for the treatment ...
Posted by Michael Wonder on 06 Feb 2023
China’s 2022 NRDL readout
7 February 2023 - Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement ...
Posted by Michael Wonder on 06 Feb 2023
TLV proposes a new process for health economic assessments that are made in a short time and under special circumstances
1 February 2023 - In a report to the government, the Dental and Pharmaceutical Benefits Agency, TLV, presents experiences and lessons ...
Posted by Michael Wonder on 06 Feb 2023
Actions to support the development of medicines for children
6 February 2023 - Regulators in the European Union have taken several initiatives in the past four years to increase the ...
Posted by Michael Wonder on 06 Feb 2023
Pharma industry urges halt to further rises in record revenue clawbacks
2 February 2023 - The pharmaceutical industry is calling on the government to scrap plans to raise the statutory revenue clawback ...